Literature DB >> 20005987

Uncoupling protein-2 and cancer.

Gyorgy Baffy1.   

Abstract

Cancer cells respond to unfavorable microenvironments such as nutrient limitation, hypoxia, oxidative stress, and host defense by comprehensive metabolic reprogramming. Mitochondria are linked to this complex adaptive response and emerging evidence indicates that uncoupling protein-2 (UCP2), a mitochondrial inner membrane anion carrier, may contribute to this process. Effects of UCP2 on mitochondrial bioenergetics, redox homeostasis, and oxidant production in cancer cells may modulate molecular pathways of macromolecular biosynthesis, antioxidant defense, apoptosis, cell growth and proliferation, enhancing robustness and promoting chemoresistance. Elucidation of these interactions may identify novel anti-cancer strategies. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20005987     DOI: 10.1016/j.mito.2009.12.143

Source DB:  PubMed          Journal:  Mitochondrion        ISSN: 1567-7249            Impact factor:   4.160


  44 in total

1.  UCP2- and non-UCP2-mediated electric current in eukaryotic cells exhibits different properties.

Authors:  Ruihua Wang; K C MoYung; M H Zhang; Karen Poon
Journal:  Environ Sci Pollut Res Int       Date:  2015-08-15       Impact factor: 4.223

2.  UCP2 knockout suppresses mouse skin carcinogenesis.

Authors:  Wenjuan Li; Chunjing Zhang; Kasey Jackson; Xingui Shen; Rong Jin; Guohong Li; Christopher G Kevil; Xin Gu; Runhua Shi; Yunfeng Zhao
Journal:  Cancer Prev Res (Phila)       Date:  2015-03-17

3.  UCP2 expression may represent a predictive marker of neoadjuvant chemotherapy effectiveness for locally advanced uterine cervical cancer.

Authors:  Kenji Imai; Takeshi Fukuda; Takuma Wada; Masaru Kawanishi; Reiko Tasaka; Tomoyo Yasui; Toshiyuki Sumi
Journal:  Oncol Lett       Date:  2017-05-19       Impact factor: 2.967

4.  Expression of UCP2 is associated with sensitivity to platinum-based chemotherapy for ovarian serous carcinoma.

Authors:  Masaru Kawanishi; Takeshi Fukuda; Masahiro Shimomura; Yuta Inoue; Takuma Wada; Reiko Tasaka; Tomoyo Yasui; Toshiyuki Sumi
Journal:  Oncol Lett       Date:  2018-04-27       Impact factor: 2.967

5.  KRAS-regulated glutamine metabolism requires UCP2-mediated aspartate transport to support pancreatic cancer growth.

Authors:  Susanna Raho; Loredana Capobianco; Rocco Malivindi; Angelo Vozza; Carmela Piazzolla; Francesco De Leonardis; Ruggiero Gorgoglione; Pasquale Scarcia; Francesca Pezzuto; Gennaro Agrimi; Simona N Barile; Isabella Pisano; Stephan J Reshkin; Maria R Greco; Rosa A Cardone; Vittoria Rago; Yuan Li; Carlo M T Marobbio; Wolfgang Sommergruber; Christopher L Riley; Francesco M Lasorsa; Edward Mills; Maria C Vegliante; Giuseppe E De Benedetto; Deborah Fratantonio; Luigi Palmieri; Vincenza Dolce; Giuseppe Fiermonte
Journal:  Nat Metab       Date:  2020-11-23

Review 6.  Uncoupling protein 2 and metabolic diseases.

Authors:  Annapoorna Sreedhar; Yunfeng Zhao
Journal:  Mitochondrion       Date:  2017-03-25       Impact factor: 4.160

Review 7.  Mitochondrial uncoupling protein 2 and pancreatic cancer: a new potential target therapy.

Authors:  Massimo Donadelli; Ilaria Dando; Elisa Dalla Pozza; Marta Palmieri
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

8.  Genipin-induced inhibition of uncoupling protein-2 sensitizes drug-resistant cancer cells to cytotoxic agents.

Authors:  Ryan J Mailloux; Cyril Nii-Klu Adjeitey; Mary-Ellen Harper
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

9.  Tempol protects cardiomyocytes from nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity.

Authors:  Yongmin Liu; Eunwoo Shim; Phuonggiang Nguyen; Alexander T Gibbons; James B Mitchell; Miriam C Poirier
Journal:  Toxicol Sci       Date:  2014-03-03       Impact factor: 4.849

10.  The combination of TRPM8 and TRPA1 expression causes an invasive phenotype in lung cancer.

Authors:  Gang-Jun Du; Jia-Huan Li; Wei-Jie Liu; Ying-Hui Liu; Bei Zhao; Hong-Ru Li; Xi-Dong Hou; Hong Li; Xiao-Xiao Qi; Yong-Jian Duan
Journal:  Tumour Biol       Date:  2013-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.